# Beiersdorf

> Beiersdorf is a VC fund in Hamburg backing Biotechnology and Wellness. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hamburg, Germany
- Total investments: 11
- Last investment: Dec 2025
- Lead investor: 9%
- Last updated: Aug 2026
- X (Twitter): https://www.twitter.com/beiersdorf_ag
- Website: https://oscar-and-paul.com/venture-capital

Beiersdorf is a VC fund in Hamburg focused on Biotechnology and Wellness. Beiersdorf AG is a German personal-care company based in Hamburg, manufacturing personal-care products and pressure-sensitive adhesives.

## Contacts

5 contacts available for Beiersdorf. Shizune tracks 9 team members at Beiersdorf. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/beiersdorf?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2M–$23M |
| Series A | $4.4M–$10M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 36% |
| Wellness | 2 | 18% |
| Health Care | 2 | 18% |
| Manufacturing | 2 | 18% |
| Apps | 1 | 9% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 45% |
| Seed | 3 | 27% |
| Pre-Seed | 1 | 9% |
| Venture - Series Unknown | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 27% |
| United Kingdom | 2 | 18% |
| France | 1 | 9% |
| Sweden | 1 | 9% |
| Germany | 1 | 9% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Felicitas Hackmann | Marketing Comms, Content Creation & Project Manager | 0 | https://shizune.co/investors/profile/felicitas-hackmann |
| Michael Fuchs | Brand Manager 8x4 | 0 | https://shizune.co/investors/profile/michael-fuchs-ceab |
| Sara Al Madani | Brand Ambassador | 0 | https://shizune.co/investors/profile/sara-al-madani |
| Stefan F. Heidenreich | CEO | 0 | https://shizune.co/investors/profile/stefan-f-heidenreich |
| Ulrich Schmidt | Managing Director | 0 | https://shizune.co/investors/profile/ulrich-schmidt |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Melt&Marble | Melt&Marble, formerly known as Biopetrolia, was founded patent holding firm for co-founder Professor Jens Nielsen’s research group. | $8.5M | Series A | Dec 08, 2025 |  |
| Cellvie | Cellvie develops cell-derived medicines, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.Mitochondria are at the heart of complex life's origin. Likely a bacterium at the time, the would-be-organelle merged with a simple organism, entering into a symbiotic relationship: The mitochondria began supplying theenergy for elaborate cellular functions to evolve, while the organism provided the mitochondria with an environment to thrive. Today, mitochondria are found in all human cells, except for red blood cells. They take on a pivotal role in cellular fate, as they produce most of the energy (ATP) and are involved in a large number of cellular and metabolic processes. The density of the organelles is particularly high in cells requiring a lot of cellular energy - e.g. cardiomyocytes or brain cells.Mitochondria function, and hence energy supply to the cell, may be impaired due to acute insults (e.g. ischemia) or genetic disorders (e.g. LOHN).Researchers at Harvard University developed an approach for mitochondria augmentation and replacement to ameliorate the damages from ischemia-reperfusion injury. Ischemia is a lack of blood flow leading to an undersupply of oxygen and an impairment of mitochondria function. Reperfusion describes the re-introduction of blood flow, inducing an oversupply of oxygen. Both, ischemia and reperfusion, damage cells, with the mitochondria dysfunction being at the heart of the injury. The cascade of events, from ischemia to reperfusion, will eventually lead to cell death. The most prominent acute conditions associated with ischemia-reperfusion injury are heart attacks. At Cellvie, we are developing a means to transplant viable mitochondria into the compromised cells, to interrupt the said cascade of events, re-enabling the cells to turn oxygen into energy via the mitochondria. | $5M | Seed | Sep 09, 2025 |  |
| ReVentas | ReVentas is dedicated to transforming how the world recycles plastics, aiming for a sustainable and circular economy. |  | Series A | May 26, 2025 |  |
| DePoly | DePoly is a chemical recycling company that converts post-consumer PET plastic and polyester textiles back into their main raw components at room temperature, without the need to pre-wash, pre-sort, or separate out other plastics. The raw material can then be sold back to the industry so that new virgin-quality plastic items can be made, creating atruly circular plastic economy. | $23M | Seed | Apr 29, 2025 |  |
| Vincere Biosciences | Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M | Series A | Apr 01, 2025 |  |
| DeepLife | DeepLife uses deep learning on multi-omics data to model cells and efficiently engineer their behavior.DeepLife is a biotech company with a mission to build the next generation of system biology. The company works in a highly collaborative translational manner, to facilitate the transition of discoveries from the laboratory to patients. Thecompany operates through collaboration with academic groups in their respective areas of expertise. | $10M | Series A | Dec 11, 2024 |  |
| DePoly | DePoly is a chemical recycling company that converts post-consumer PET plastic and polyester textiles back into their main raw components at room temperature, without the need to pre-wash, pre-sort, or separate out other plastics. The raw material can then be sold back to the industry so that new virgin-quality plastic items can be made, creating atruly circular plastic economy. | $13.8M | Seed | Jun 27, 2023 |  |
| Salvalco | Salvalco Eco-Valves are new aerosol valves specifically designed to enable aerosols to be propelled successfully by harmless gases such as Nitrogen, Carbon Dioxide or simply Compressed Air. | $3.1M | Venture - Series Unknown | May 16, 2022 |  |
| Dermanostic | Dermanostic is an e-health app where patients receive a medical diagnosis and therapy recommendation for skin diseases. | $2M | Seed | Jan 11, 2022 |  |
| Routinely | Routinely is an online store that sells skincare products. Their products include cleaners, moisturizers, and serums. They allow consumers to directly buy goods or services from a seller over the internet. Their products serve consumers. |  | Pre-Seed | May 20, 2020 |  |

10 of 11 investments shown.

## Co-investors
- [Founderful](https://shizune.co/investors/profile/wingman-897a) — VC Fund, 4 deals together
- [Angel Invest](https://shizune.co/investors/profile/angel-invest-ventures) — VC Fund, 2 deals together
- [BASF Venture Capital](https://shizune.co/investors/profile/basf-venture-capital) — VC Fund, 2 deals together
- [Green Angel Ventures](https://shizune.co/investors/profile/green-angel-syndicate) — VC Fund, 2 deals together
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund, 2 deals together
- [Ninepointfive](https://shizune.co/investors/profile/9-5-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Energy VC Funds in Switzerland](https://shizune.co/investors/energy-vc-funds-switzerland)
- [Sustainability Investors in Switzerland](https://shizune.co/investors/sustainability-investors-switzerland)
- [Sustainability VC Funds in Switzerland](https://shizune.co/investors/sustainability-vc-funds-switzerland)
- [Impact Investors in Switzerland](https://shizune.co/investors/impact-investors-switzerland)
- [Impact VC Funds in Switzerland](https://shizune.co/investors/impact-vc-funds-switzerland)

## FAQ

### What does Beiersdorf invest in?

Beiersdorf invests primarily in Biotechnology, Wellness and Health Care startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Beiersdorf's check size?

Beiersdorf typically joins rounds of $2M–$23M at Seed and $4.4M–$10M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Beiersdorf participates in.

### How do I contact Beiersdorf?

Public channels for Beiersdorf include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Beiersdorf?

The team at Beiersdorf includes Felicitas Hackmann (Marketing Comms, Content Creation & Project Manager), Michael Fuchs (Brand Manager 8x4) and Sara Al Madani (Brand Ambassador), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co